Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 5 de 5
Filtrar
Adicionar filtros








Intervalo de ano
1.
Braz. J. Pharm. Sci. (Online) ; 58: e191142, 2022. tab, graf
Artigo em Inglês | LILACS | ID: biblio-1394056

RESUMO

A series of N-(benzoylphenyl)-carboxamide derivatives (2a, 2b, 3a, 3b, 4a, 4b, 5a, 5b, 6a and 6b) was prepared with good yields by reacting the corresponding carbonyl chlorides with aminobenzophenones at room temperature. This was followed by evaluating the hypotriglyceridemic and hypocholesterolemic effects of 3b, 5a and 5b. Triton WR-1339 (300 mg/kg) was intraperitoneally administered to overnight-fasted rats to induce hyperlipidemia. Rats were divided into six groups: control, hyperlipidemic, hyperlipidemic plus compounds 3b, 5a and 5b and hyperlipidemic plus bezafibrate. Results showed that after 18 h of treatment at a dose of 15 mg/kg body weight of each of the test compounds, the elevated plasma levels of triglycerides (TG) and total cholesterol (TC) were significantly lowered by compounds 5b and 3b (p < 0.001) and by 5a (p < 0.0001), compared to the hyperlipidemic control group. Compounds 3b and 5a significantly increased levels of high-density lipoprotein cholesterol (HDL-C) by 58 and 71%, respectively. In addition, compounds 3b and 5a caused significant reduction (p < 0.0001) of low-density lipoprotein cholesterol (LDL-C) levels compared to the control group. These results suggest a promising potential for compounds 3b, 5a and 5b as lipid-lowering agents, which may contribute to reducing the risk of atherosclerosis and cardiovascular disease


Assuntos
Animais , Masculino , Ratos , Piridinas/farmacologia , Hiperlipidemias/induzido quimicamente , Lipídeos/sangue , Hipolipemiantes/farmacologia , Polietilenoglicóis , Piridinas/síntese química , Triglicerídeos/sangue , Colesterol/sangue , Ratos Wistar , Modelos Animais de Doenças , Lipoproteínas HDL/efeitos dos fármacos , Lipoproteínas LDL/efeitos dos fármacos , Hipolipemiantes/síntese química
2.
Biol. Res ; 51: 34, 2018. tab, graf
Artigo em Inglês | LILACS | ID: biblio-983938

RESUMO

BACKGROUND AND AIMS: Atherosclerotic cardiovascular disease is highly prevalent and its underlying pathogenesis involves dyslipidemia including pro-atherogenic high density lipoprotein (HDL) remodeling. Vitamins C and E have been proposed as atheroprotective agents for cardiovascular disease management. However, their effects and benefits on high density lipoprotein function and remodeling are unknown. In this study, we evaluated the role of vitamin C and E on non HDL lipoproteins as well as HDL function and remodeling, along with their effects on inflammation/ oxidation biomarkers and atherosclerosis in atherogenic diet-fed SR-B1 KO/ApoER61h/h mice. METHODS AND RESULTS: Mice were pre-treated for 5 weeks before and during atherogenic diet feeding with vitamin C and E added to water and diet, respectively. Compared to a control group, combined vitamin C and E administration reduced serum total cholesterol and triglyceride levels by decreasing apo B-48-containing lipoproteins, remodeled HDL particles by reducing phospholipid as well as increasing PON1 and apo D content, and diminished PLTP activity and levels. Vitamin supplementation improved HDL antioxidant function and lowered serum TNF-α levels. Vitamin C and E combination attenuated atherogenesis and increased lifespan in atherogenic diet-fed SR-B1 KO/ApoER61h/h mice. CONCLUSIONS: Vitamin C and E administration showed significant lipid metabolism regulating effects, including HDL remodeling and decreased levels of apoB-containing lipoproteins, in mice. In addition, this vitamin supplementation generated a cardioprotective effect in a murine model of severe and lethal atherosclerotic ischemic heart disease.


Assuntos
Animais , Masculino , Feminino , Ácido Ascórbico/farmacologia , Vitamina E/farmacologia , Isquemia Miocárdica/prevenção & controle , Apolipoproteína B-48/efeitos dos fármacos , Hiperlipidemias/prevenção & controle , Lipoproteínas HDL/efeitos dos fármacos , Antioxidantes/farmacologia , Valores de Referência , Doença da Artéria Coronariana/prevenção & controle , Doença da Artéria Coronariana/sangue , Ensaio de Imunoadsorção Enzimática , Cardiotônicos/farmacologia , Immunoblotting , Reprodutibilidade dos Testes , Citocinas/sangue , Resultado do Tratamento , Isquemia Miocárdica/sangue , Suplementos Nutricionais , Proteínas de Transferência de Fosfolipídeos/sangue , Dieta Aterogênica , Receptores Depuradores Classe B/efeitos dos fármacos , Receptores Depuradores Classe B/sangue , Metabolismo dos Lipídeos/efeitos dos fármacos , Apolipoproteína B-48/sangue , Hiperlipidemias/sangue , Lipoproteínas HDL/sangue , Camundongos Endogâmicos C57BL
3.
Rev. chil. infectol ; 31(1): 34-43, feb. 2014. ilus
Artigo em Espanhol | LILACS | ID: lil-706544

RESUMO

High density lipoproteins (HDL) are responsible of reverse cholesterol transport and play an important antiatherogenic role. In recent years, several studies suggest that HDL have additional functions, including a possible anti-inflammatory activity in infectious conditions. Furthermore, available evidence indicates that the presence of lipopolysaccharide (LPS) within the circulation during infectious states induced by gram-negative bacteria may be involved in the decrease in HDL cholesterol levels and changes in lipoprotein composition, which have been associated with a higher mortality due to sepsis in animal models and in humans. In this article, we review this subject and also discuss possible mechanisms that explain the positive impact achieved by native HDL, reconstituted HDL, or HDL apolipoprotein peptides on the inflammatory response and mortality in models of endotoxemia. In this regard, it has been proposed that one of the mechanisms by which HDL protect against sepsis may be mediated by its binding ability and/or neutralizing capacity on LPS, avoiding an excessive response of the immune system. Thus, increasing blood levels of HDL and/or parenteral HDL administration may represent a new anti-inflammatory tool for managing septic states in humans.


Las lipoproteínas de alta densidad (HDL) son responsables del transporte reverso de colesterol y ejercen un importante papel anti-aterogénico. En los últimos años, diversos estudios indican que las HDL también tendrían otras funciones críticas, incluyendo una posible actividad anti-inflamatoria durante estados infecciosos. Además, la evidencia disponible sugiere que la presencia de lipopolisacárido (LPS) en la circulación durante estados infecciosos inducidos por bacterias gramnegativas podría estar involucrado en la disminución del colesterol HDL y los cambios en composición de esta clase lipoproteínas, lo cual se asociaría con una mayor tasa de mortalidad por sepsis en modelos animales y en humanos. En este trabajo, se revisan los antecedentes mencionados y además se discuten posibles mecanismos que explican la disminución de la respuesta inflamatoria y de la mortalidad que se logran en modelos de endotoxemia tratados con HDL o preparaciones similares. En este sentido, se ha propuesto que uno de los mecanismos protectores de las HDL estaría mediado por su capacidad de unión y/o neutralización del LPS, evitando una respuesta exacerbada del sistema inmune. De esta manera, el aumento de los niveles sanguíneos de HDL y/o su administración parenteral podrían constituir nuevas herramientas anti-inflamatorias para el manejo de estados sépticos en humanos.


Assuntos
Animais , Humanos , Camundongos , Aterosclerose/prevenção & controle , Endotoxemia/imunologia , Lipoproteínas HDL/fisiologia , Estresse Oxidativo/fisiologia , Sepse/imunologia , Anti-Inflamatórios/farmacologia , Apolipoproteína A-I/análise , Colesterol/sangue , Modelos Animais de Doenças , Endotoxemia/sangue , Mediadores da Inflamação/metabolismo , Inflamação/sangue , Inflamação/imunologia , Lipopolissacarídeos/sangue , Lipoproteínas HDL/sangue , Lipoproteínas HDL/efeitos dos fármacos , Sepse/sangue , Trombose/sangue
5.
PJMR-Pakistan Journal of Medical Research. 1988; 27 (2): 86-91
em Inglês | IMEMR | ID: emr-95056

RESUMO

The study was aimed at evaluating the effects of sulphonyhireas on senlni HDL-cholesterol and its subJracdials ill type diabetes mellitus. Sixty three non-obese, newly diagnosed diabetic patients with a short history of disease were studied before and after treatment with sulphaiyhireas for a period of 6 months. We observed highly significant increases in total HDL and HDL-cholesterol after therapy. The HDL3 cholesterol did not change after therapy in the majority of patients and post-therapy rise of total HDL- cholesterol was almost entirely due to a rise in HDL2 cholestrol. Thus, we may conclude that HDL2 cholesterol is more important than HDL-cholesterol in the causation of atherosclerosis. The HDL2 cholesterol levels may predict the development of coronary atherosclerosis


Assuntos
Humanos , Colesterol/sangue , Lipoproteínas HDL/efeitos dos fármacos , Lipídeos , Compostos de Sulfonilureia/administração & dosagem
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA